Abstract
Dyslipidemia is a major risk factor for atherosclerosis, and high low-density lipoprotein (LDL) cholesterol is closely associated with the onset of atherosclerotic cardiovascular disease (ASCVD), including coronary artery disease. Numerous large-scale clinical trials have demonstrated that LDL cholesterol-lowering therapy, primarily involving statins, reduces not only coronary events, but also stroke, and has been established as a cornerstone of cardiovascular prevention. However, ischemic stroke is a group of diseases comprising different pathologies, such as atherothrombotic stroke, cardioembolic stroke, and small-vessel disease; the involvement of dyslipidemia and the efficacy of lipid-lowering therapy vary significantly depending on the subtype. Therefore, the evidence established for coronary artery disease cannot necessarily be applied directly to stroke management, and establishing lipid management strategies tailored to each subtype has become a critical challenge in stroke management. Furthermore, in recent years, in addition to LDL cholesterol-lowering therapy, treatments targeting hypertriglyceridemia, lipoprotein(a) [Lp(a)], and residual inflammatory risk have advanced, and the development of new therapeutic agents—such as PCSK9 inhibitors, selective PPARα modulators, and ATP citrate lyase inhibitors—is progressing, thus raising expectations for their application in stroke prevention. This article provides an overview of domestic and international guidelines for dyslipidemia and summarizes the association between dyslipidemia and ischemic stroke from the perspectives of pathophysiology, pathological findings, and imaging and blood biomarker. In addition, it outlines the latest evidence from large-scale clinical trials, new lipid-lowering therapies, acute-phase lipid management, and interventions targeting residual risk, and discusses the current status and future prospects of lipid management tailored to specific stroke subtypes.
Keywords: Dyslipidemia, Ischemic stroke, Statin, LDL, Lipid-lowering therapy
1. Treatment of Dyslipidemia in the Guidelines (A Comparison of Japan, the U.S., and Europe)
According to Japanese diagnostic criteria for dyslipidemia, low-density lipoprotein cholesterol (LDL-C) of 140 mg/dL or higher is defined as high LDL cholesterol, high-density lipoprotein cholesterol (HDL-C) of less than 40 mg/dL as low HDL cholesterol, and non-HDL-C of 170 mg/dL or higher as high non-HDL cholesterol. Hypertriglyceridemia is defined as fasting triglyceride (TG) levels of ≥ 150 mg/dL or random TG levels of ≥ 175 mg/dL 1) . In the Hisayama Study conducted in Japan, a significant positive association was observed between LDL-C levels and the risk of atherothrombotic cerebral infarction, similar to that observed in coronary artery disease 2) . High total cholesterol (T-CHO) levels, low HDL-C levels, and hypertriglyceridemia have also been reported to be associated with an increased risk of ischemic stroke 3 - 5) .
The American College of Cardiology/American Heart Association (ACC/AHA) guidelines in the United States do not establish uniform criteria for diagnosing “dyslipidemia” based solely on a single lipid value and determining treatment interventions in a uniform manner, as is done in Japan. Dyslipidemia is treated as a concept that encompasses high LDL cholesterol, high TG, low HDL cholesterol, and elevated lipoprotein(a) [Lp(a)], among others; in addition to the evaluation of individual lipid abnormalities, the intensity and strategy of therapeutic intervention are determined based on a comprehensive assessment of atherosclerotic cardiovascular disease (ASCVD) risk, including age, blood pressure, and smoking status to determine the intensity and strategy of therapeutic intervention 6) . Historically, in the United States, the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) classification of lipid levels has been widely used, defining LDL-C levels of 160–189 mg/dL as high, 190 mg/dL or higher as very high, and TG levels of 200–499 mg/dL as high, and 500 mg/dL or higher as very high 7) . However, these are classifications of lipid level severity and do not constitute the comprehensive diagnostic criteria or absolute treatment initiation criteria outlined in the current ACC/AHA guidelines. The European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines also emphasize the importance of assessing a patient’s cardiovascular risk category and setting LDL cholesterol management targets accordingly, rather than relying on a diagnosis based on a single lipid value 8) .
While Japan clearly specifies diagnostic and screening criteria based on lipid levels, Europe and the United States place greater emphasis on evaluating individual dyslipidemias and implementing comprehensive therapeutic interventions based on cardiovascular risk (risk-based approach) ( Table 1 ) . In Japan, LDL cholesterol management targets are set based on absolute risk assessments derived from the Hisayama Study. For primary prevention, the targets are less than 160, 140, and 120 mg/dL for low, moderate, and high risk, respectively; for secondary prevention, the target is less than 100 mg/dL. Furthermore, in particularly high-risk cases, such as those with acute coronary syndrome, familial hypercholesterolemia, diabetes, or a combination of coronary artery disease and atherothrombotic stroke, more stringent lipid management with a target LDL-C level of less than 70 mg/dL is considered. According to the 2026 U.S. guidelines, treatment indications and intensity are determined based on the 10-year ASCVD risk as assessed by PREVENT. When initiating lipid-lowering therapy, the management targets are an LDL-C level below 100 mg/dL for borderline-to-intermediate risk and below 70 mg/dL for high risk. For secondary prevention, the target is less than 55 mg/dL for ultra-high-risk ASCVD patients and less than 70 mg/dL for other ASCVD patients; if these targets are not met, the addition of non-statin medications should be considered. The European Society of Cardiology/European Atherosclerosis Society guidelines set targets of less than 116, 100, 70, and 55 mg/dL for low-, moderate-, high-, and very high-risk groups, respectively, and also require a reduction of at least 50% from baseline for high-risk and higher groups.
Table 1. Comparison of Lipid Management Recommendations in Current Guidelines.
| Japan (JAS 2022) | United States (ACC/AHA 2026) | Europe (ESC/EAS 2025) | |
|---|---|---|---|
| Basic Management Strategy | Risk category–based LDL-C target values | PREVENT-ASCVD risk category– based LDL-C targets and LDL-C reduction rate | Risk category–based LDL-C target values and LDL-C reduction rate |
| Risk Assessment | Comprehensive atherosclerotic cardiovascular disease risk categories | PREVENT-ASCVD 10-year risk | SCORE2 / SCORE2-OP |
| Low Risk | LDL-C <160 mg/dL | <3%: Lifestyle modification | LDL-C <116 mg/dL |
| Borderline Risk | — | 3% to <5%: LDL-C <100 mg/ dL; consider moderate-intensity statin therapy | — |
| Intermediate Risk | LDL-C <140 mg/dL | 5% to <10%: LDL-C <100 mg/ dL; moderate- to high-intensity statin therapy | LDL-C <100 mg/dL |
|
High Risk (Primary Prevention) |
LDL-C <120 mg/dL | ≥ 10%: LDL-C <70 mg/dL; high- intensity statin therapy | LDL-C <70 mg/dL |
| Diabetes Mellitus |
Generally LDL-C <100 mg/dL according to comorbidities |
LDL-C <100 or <70 mg/dL depending on risk |
LDL-C <55 mg/dL in high-risk patients |
| Secondary Prevention | LDL-C <100 mg/dL | LDL-C <70 mg/dL | LDL-C <55 mg/dL |
|
Very High-Risk Secondary Prevention |
LDL-C <70 mg/dL | LDL-C <55 mg/dL | LDL-C <55 mg/dL Extreme risk, <40 mg/dL |
| Recommended LDL-C Reduction | No specific recommendation | ≥ 50% LDL-C reduction with high- intensity statin therapy | ≥ 50% LDL-C reduction recommended |
JAS 2022: Management is primarily based on LDL-C target values.
ACC/AHA 2026: The guideline uses the PREVENT-ASCVD 10-year risk categories (Low <3%, Borderline 3–<5%, Intermediate 5–<10%, High ≥ 10%) and reintroduces LDL-C targets. The recommended LDL-C target is <100 mg/dL for Borderline and Intermediate-risk individuals, <70 mg/dL for High-risk individuals, and <55 mg/dL for patients with very high-risk ASCVD.ESC/EAS 2025: The guideline uses risk stratification based on SCORE2/SCORE2-OP and recommends LDL-C target values (116, 100, 70, and 55 mg/dL) together with a ≥ 50% reduction in LDL-C from baseline.
2.The Role of Dyslipidemia by Type of Cerebral Infarction
A pathological examination of carotid lesions revealed that plaques with a high proportion of macrophage infiltration were unstable and had high concentrations of oxidized LDL 9) . It has been shown that the proportion of hyperechoic plaques observed on carotid ultrasound increases as the HDL-C levels decrease, and that the degree of stenosis becomes more severe 10) . The relationship between plaque characteristics and serum lipid biomarkers is complex; the presence of a lipid-rich core is not associated with individual markers such as LDL-C, ApoB, or non-HDL-C, but it has been reported to be associated with lipid ratios such as the T-CHO/HDL-C ratio and the non-HDL-C/HDL-C ratio 11) . Studies using magnetic resonance imaging (MRI) to evaluate carotid plaques over time have also reported that lipid-lowering therapy can lead to a reduction in lipid-rich necrotic cores 12) .
Similarly, numerous studies have linked intracranial vascular stenosis to dyslipidemia. In a study using contrast-enhanced MRI, the group with strong contrast enhancement in the intracranial vessels had higher LDL-C and non-HDL-C levels 13) . However, while the presence of intracranial vascular stenosis is associated with high LDL-C and low HDL-C levels, some reports indicate that this relationship differs when stenosis is defined as 50% or greater 14) . In a study examining multiple biomarkers, the combination of LDL-C ≥ 100 mg/dL and remnant cholesterol (calculated as T-CHO − LDL-C − HDL-C) ≥ 22 mg/dL increased the diagnostic sensitivity for intracranial stenosis 15) . The efficacy of dyslipidemia treatment in patients with intracranial stenosis has also been suggested. In the WASID intracranial stenosis cohort, the group with T-CHO levels of 200 mg/dL or higher had a significantly higher rate of the composite endpoint of stroke recurrence, myocardial infarction, and cardiovascular death than that of the group with levels below 200 mg/dL 16) . The SAMMPRIS trial compared intracranial stenting with medical therapy; the results suggested that intensified medical therapy, including blood pressure control, dual antiplatelet therapy (DAPT), lifestyle modifications, and controlling LDL-C to 70 mg/dL, may have contributed to favorable outcomes 17) .
In a study using transesophageal echocardiography (TEE), elevated T-CHO levels were associated with the extent of plaque in the descending thoracic aorta, regardless of whether the patient had familial or nonfamilial hypercholesterolemia 18) . Studies have also shown that this relationship is clarified by the LDL-C/HDL-C ratio 19) . There are also reports indicating that one year of atorvastatin administration resulted in a reduction in LDL-C levels as well as regression of thoracic aortic plaques observed on MRI 20) . There are reports indicating that while LDL-C and T-CHO levels showed no independent association, low HDL-C levels and a high ApoB/ApoA-I ratio were associated with aortic atherosclerosis 21) .
Studies focusing on lacunar infarction and branch atheromatous disease have not consistently yielded similar results. One report indicated that patients with advanced perforating artery infarction in the anterior circulation had elevated LDL-C and TG levels, whereas similar findings were not observed in patients with infarction in the posterior circulation 22) , whereas other studies on lacunar infarction and branch atheromatous disease have found no difference in the history of dyslipidemia between the two groups 23) . Other studies have suggested that the TG/HDL-C ratio is associated with progressive cerebral infarction 24) . There are reports indicating that apolipoprotein A-1 concentration, the apoB/apoA-1 ratio, and HDL-C levels are associated with disease progression 25) , and there are also reports demonstrating the usefulness of the TyG index (log [fasting (TG × blood glucose)/2]) 26) .
In recent years, studies have been published that simultaneously evaluated dyslipidemia and inflammation. Elevated levels of C-reactive protein (CRP), a biomarker of inflammation, have been shown to be a risk factor for ischemic stroke, similar to that of coronary artery disease 27) . In patients with acute ischemic stroke, elevated CRP levels, excluding those due to infection, were associated with poor short-term outcomes 28) . In a 30-year follow-up study, the combination of elevated high-sensitivity CRP (hs-CRP), LDL-C, and Lp(a) was a predictor of long-term cardiovascular risk 29) Furthermore, a risk assessment integrating dyslipidemia and inflammation yielded similar results for the onset of ischemic stroke 30) .
3.Atherosclerotic Mechanisms of Major Lipoproteins
LDL-C is the principal atherogenic lipoprotein and it plays a central role in the initiation and progression of atherosclerosis. LDL particles infiltrate the arterial intima, undergo oxidative modification, and are taken up by macrophages through scavenger receptors, leading to foam-cell formation and vascular inflammation. Unlike other major lipoproteins, Lp(a) concentrations are largely genetically determined, remain stable throughout adulthood, and are minimally influenced by lipid-lowering therapies. Structurally, Lp(a) is an LDL-like particle in which apolipoprotein(a) is covalently bound to apolipoprotein B-100 (ApoB100). Lp(a) serves as a major carrier of pro-inflammatory oxidized phospholipids and exerts antifibrinolytic effects owing to the structural homology between apolipoprotein(a) and plasminogen 31) . Although HDL-C has traditionally been regarded as a protective lipoprotein, recent studies have suggested that extremely high HDL-C levels (hyper-HDL-cholesterolemia) are not necessarily associated with a lower cardiovascular risk and may instead be associated with increased mortality 32) . The mechanisms underlying this paradox remain incompletely understood; however, HDL dysfunction, characterized by impaired cholesterol efflux capacity and reduced anti-inflammatory and antioxidant properties, may explain this association 33) .
Although the association between hypertriglyceridemia and vascular risk is less consistent than that of LDL-C, it is largely mediated by triglyceride-rich lipoproteins (TRLs) and their cholesterol-rich remnants rather than by triglyceride molecules 34) . TRLs comprise chylomicrons, very-low-density lipoproteins (VLDL), and their remnant particles, including intermediate-density lipoproteins (IDL). Their remnant particles can directly penetrate the arterial wall and induce foam cell formation without prior oxidative modification. Furthermore, the accumulation promotes cholesteryl ester transfer protein (CETP)-mediated exchange of cholesteryl esters and triglycerides among HDL, VLDL, IDL, and LDL, resulting in triglyceride-enriched LDL particles that are subsequently hydrolyzed by hepatic lipase to form small dense LDL (sdLDL) 35) . Compared with larger LDL particles, sdLDL penetrates the arterial wall more readily and is more susceptible to oxidative modification. The reduced affinity of sdLDL for the LDL receptor prolongs its plasma residence time, facilitating macrophage uptake and foam cell formation. Because LDL, TRL remnants, and Lp(a) contain ApoB, the total number of ApoB particles is recognized as a key indicator of vascular risk.
4.History of Lipid-Lowering Therapy and the Introduction of Various Drugs
4-1. The Emergence of Statins
In the 1960s and the 1970s, studies such as the Framingham Study revealed that high LDL-C levels are a major risk factor for atherosclerosis and coronary artery disease 36 , 37) . However, the efficacy of lowering LDL-C in reducing cardiovascular events had not yet been proven. In 1976, Endo et al. A and colleagues discovered ML-236B (compactin, mevastatin), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, in Penicillium citrinum 38) . Merck & Co. developed lovastatin (mevinolin) from Aspergillus terreus, which was approved in 1987 as the world’s first commercially available statin. Subsequently, simvastatin, pravastatin, atorvastatin, and rosuvastatin were developed one after another, and statins became the cornerstone of lipid-lowering therapy. Since then, numerous large-scale clinical studies focusing on statins have been performed 39) .
4-2. Drugs for Dyslipidemia Other Than Statins
In addition to statins, other drugs used clinically to treat dyslipidemia include fibrates, n-3 polyunsaturated fatty acid preparations, cholesterol absorption inhibitors, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, selective peroxisome proliferator-activated receptor alpha (PPARα) modulators (SPPARMα), and ATP citrate lyase (ACL) inhibitors. Fibrates have been used since the 1960s; they lower TG and raise HDL-C levels by activating PPARα and are used to treat dyslipidemia characterized primarily by hypertriglyceridemia. Eicosapentaenoic acid ethyl ester, an n-3 polyunsaturated fatty acid preparation, was introduced into clinical practice in the 1990s; it lowers TG levels by inhibiting TG synthesis in the liver and promoting fatty acid β-oxidation. Ezetimibe, a cholesterol absorption inhibitor introduced in the 2000s, suppresses cholesterol absorption by inhibiting Niemann–Pick C1-Like 1 (NPC1L1) in the brush border of the small intestine, thereby lowering LDL-C levels. PCSK9 inhibitors were introduced into clinical practice in the 2010s. By inhibiting the degradation of LDL receptors by PCSK9, they increase the number of LDL receptors on the surface of hepatocytes, thereby exerting a potent LDL-C-lowering effect. Pemafibrate is an SPPARMα that was introduced into clinical practice in the late 2010s. By enhancing the selectivity for PPARα compared to conventional fibrate drugs, it aims to lower TG levels while improving safety. Furthermore, bempedoic acid, an ACL inhibitor, has been clinically used in recent years; it lowers LDL-C by inhibiting the cholesterol synthesis pathway upstream of HMG-CoA reductase ( Fig.1 ) . Along with the development of these drugs, numerous large-scale clinical trials have been conducted to verify their respective efficacies, leading to the accumulation of evidence for lipid-lowering therapy. The major clinical trials are summarized below.
Fig.1.

Development of Lipid-Lowering Therapies
5.Large-Scale Clinical Studies on Lipid-Lowering Therapy ( Fig.2 )
Fig.2.

Major Clinical Trials of Lipid-Lowering Therapy (1987–2016)
5-1. Evidence for Primary Prevention
Large-scale clinical trials on the primary prevention of dyslipidemia include the Helsinki Heart Study, WOSCOPS, ASCOT-LLA, CARDS, and HOPE-3, which expanded their scope to include moderate-risk patients. The Helsinki Heart Study, reported in 1987, enrolled 4,081 middle-aged men to evaluate the efficacy of gemfibrozil in patients with dyslipidemia and non-HDL-C levels of ≥ 200 mg/dL, and the results showed a 34% reduction in the risk of developing ischemic heart disease 40) . The WOSCOPS study, reported in 1995, evaluated the efficacy of pravastatin in 6,595 men without a history of coronary artery disease (mean baseline LDL-C 192 mg/dL) and found a 31% reduction in the incidence of ischemic heart disease 41) . Furthermore, in the ASCOT-LLA study reported in 2003, 10,305 patients (mean baseline LDL-C 133 mg/dL) with hypertension and three or more cardiovascular risk factors were treated with atorvastatin 10 mg daily, resulting in a 27% reduction in the risk of stroke 42) . In the CARDS study reported in 2004, the efficacy of atorvastatin 10 mg/day was evaluated in 2,838 patients with type 2 diabetes and no history of cardiovascular disease (mean baseline LDL-C 118 mg/dL), and the risk of stroke was reduced by 48% 43) . The HOPE-3 study was reported in 2016. In this study, 12,705 moderate-risk patients with no history of cardiovascular disease were administered rosuvastatin 10 mg/day. The mean baseline LDL-C level was 128 mg/dL, and the incidence of stroke was reduced by 30% 44) . These trials demonstrated that statin therapy for primary prevention may be effective in reducing not only cardiovascular events but also the incidence of stroke, even in high-risk patients whose LDL-C levels are not markedly elevated.
5-2. Evidence for Early Secondary Prevention and Specific Clinical Conditions
Large-scale clinical trials on secondary prevention began with the 4S trial, reported in 1994. The 4S study was the first to demonstrate that simvastatin significantly reduced overall mortality and coronary events in patients with coronary artery disease undergoing secondary prevention 45) . The 4S study reported that the mean baseline LDL-C level was 188 mg/dL and that the incidence of stroke was reduced by approximately 30%. The 1996 CARE trial included 4,159 patients with a history of myocardial infarction and a mean LDL-C level of 139 mg/dl. Pravastatin treatment reduced the incidence of stroke by 31% 46) . In the 1998 LIPID trial, which included 9,014 patients with a history of coronary artery disease (mean LDL-C level of 150 mg/dL), pravastatin was administered, and the incidence of stroke was reduced by 19% 47) . Although stroke was not a primary endpoint in these trials, they demonstrated a preventive effect, which served as a catalyst for accumulating evidence supporting statin therapy in the field of stroke management.
Studies targeting specific elderly populations and patients with kidney disease have also been conducted. The PROSPER trial, reported in 2002, enrolled 5,804 elderly patients aged 70–82 years (with existing vascular disease or risk factors) and administered pravastatin 40 mg/day. Although coronary heart disease was reduced by 19%, no effect on stroke prevention was observed 48) . In 2011, the SHARP trial was reported. In this study, 9,438 patients with chronic kidney disease received combination therapy with simvastatin (20 mg/day) and ezetimibe (10 mg/day). The mean baseline LDL-C level was 108 mg/dL, and the incidence of ischemic stroke was significantly reduced by approximately 28% 49) .
5-3. Evidence for Intensive LDL-C Lowering Therapy
The HPS study, published in 2002, evaluated the efficacy of 40 mg simvastatin in a high-risk population with a history of coronary artery disease, diabetes, or stroke. The mean baseline LDL-C level was 131 mg/dL, and the achieved LDL-C level was 97 mg/dL. Consequently, the incidence of stroke was reduced by 25% 50) . In 2005, the TNT study enrolled patients with a history of coronary artery disease and employed a protocol to compare the efficacy of atorvastatin 80 mg (vs. 10 mg) after lowering LDL-C levels to below 130 mg/dL (mean 98 mg/dL). The mean LDL-C level achieved was 77 mg/dL, and the incidence of stroke was reduced by 25% 51) . In 2015, the IMPROVE-IT study was conducted. This study compared combination therapy with simvastatin and ezetimibe to simvastatin monotherapy in patients with a history of coronary artery disease (CAD). The average LDL-C level achieved was 54 mg/dL, and the incidence of ischemic stroke was reduced by 21% 52) . In 2017, the FOURIER trial evaluated combination therapy with a statin and PCSK9 inhibitor. The achieved LDL-C level decreased significantly from an average of 92 mg/dL to 30 mg/dL, and the incidence of ischemic stroke decreased by 25% 53) . Subsequently, in 2022, follow-up results spanning up to 8.4 years were reported, supporting the long-term durability of the clinical benefits observed in the parent study 54) . In 2026, the results of the EZ-PAVE trial were reported, which evaluated intensive LDL-lowering therapy (combination therapy with statins and ezetimibe vs. statin monotherapy) in East Asian patients with ASCVD. The mean LDL-C level achieved was 56 mg/dL (vs. 66 mg/dL), and the primary composite outcome (cardiovascular death, myocardial infarction, stroke, coronary revascularization, and hospitalization for unstable angina) was reduced by 33%. A detailed analysis revealed that the reduction was particularly pronounced for myocardial infarction and revascularization procedures; however, no significant difference was observed for stroke 55) .
5-4. Meta-analysis and Safety (CTT Analysis and Muscle Disorders)
The meta-analysis “Cholesterol Treatment Trialists’ (CTT) Collaboration,” reported in 2010, was based on 26 large-scale RCTs 56) and is representative evidence demonstrating the stroke-preventive effects of LDL-C-lowering therapy. This analysis examined the relative risk (RR) for each 1.0 mmol/L (approximately 39 mg/dL) reduction in LDL-C, stratified by stroke subtype and treatment intensity. For ischemic stroke, 21 trials comparing standard statin therapy with a control group showed an RR of 0.80 (95% CI: 0.73–0.88), indicating a significant 20% reduction in incidence. Furthermore, in five trials evaluating more intensive statin therapy, an RR of 0.69 (95% CI: 0.50–0.95) was observed, representing a 31% reduction in incidence. A meta-analysis of all 26 trials also confirmed a clear 21% risk reduction, with an RR of 0.79 (95% CI: 0.74–0.84). Regarding intracerebral hemorrhage, although a numerical trend toward an increase was observed in 21 trials (RR 1.10, 10% increase), 5 trials (RR 1.39, 39% increase), and the meta-analysis of all 26 trials (RR 1.15, 15% increase), no statistically significant differences were found in any of these cases. For “any stroke” overall, the RR was 0.85 (15% reduction) in 21 trials, 0.74 (26% reduction) in five trials, and 0.85 (15% reduction) in the meta-analysis of all 26 trials; all of these results demonstrated a significant reduction in incidence. These results indicate that the stroke-reducing effect of aggressive LDL-C-lowering therapy is primarily due to a substantial reduction in the risk of ischemic stroke (approximately 20–30%).
Caution is required regarding the risk of muscle disorders, such as rhabdomyolysis. In the SEARCH trial, which enrolled 12,064 patients with a history of myocardial infarction, simvastatin 80 mg did not significantly reduce major vascular events compared with 20 mg, and no significant reduction in stroke was observed. However, the 80-mg group showed a markedly higher incidence of myopathy (0.9% vs. 0.03%) and an increased risk of rhabdomyolysis, raising concerns regarding the safety of high-dose simvastatin administration 57) . Genetic analyses have demonstrated that SLCO1B1 variants are strongly associated with statin-induced myopathy, highlighting the importance of individual susceptibility and careful safety monitoring during high-intensity therapy 58) .
5-5. Secondary prevention studies in patients with stroke or TIA (SPARCL, TST, etc.)
The HPS enrolled 20,536 patients with atherosclerotic vascular disease or diabetes; of these, 3,280 had a history of stroke. The mean baseline LDL-C level in patients with a history of stroke was approximately 131 mg/dL. The administration of 40 mg/day simvastatin reduced LDL-C by approximately 39 mg/dL. In the overall trial, the risk of stroke was significantly reduced by approximately 25%. However, in a subgroup analysis of patients with a history of stroke, the stroke recurrence rate was 10.3% in the simvastatin group and 10.4% in the placebo group, with no significant difference 59) .
The SPARCL trial compared atorvastatin 80 mg/day with placebo in 4,731 patients who had experienced a stroke or TIA, had no history of coronary artery disease, and had LDL-C levels between 100 and 190 mg/dL. During a mean follow-up of 4.9 years, LDL-C levels decreased by approximately 60 mg/dL in the atorvastatin group, and the risk of stroke recurrence was significantly reduced by 16% (HR (hazard ratio [HR) 0.84, 95% confidence interval [CI] 0.71–0.99, P = 0.03). However, the incidence of hemorrhagic stroke increased (55 vs. 33 cases, HR 1.66); however, the overall effect of reducing stroke recurrence was demonstrated due to the significant reduction in ischemic stroke 60) .
The efficacy of aggressive LDL-C-lowering therapy has also been demonstrated in previous studies. The TST trial compared a group with an LDL-C target of less than 70 mg/dL to a group with a target of 90–110 mg/dL in 2,860 patients with a history of ischemic stroke or TIA and atherosclerotic disease. Statins were used as the primary treatment, with ezetimibe added as needed to achieve target levels. During an average follow-up of 3.5 years, the group with LDL-C levels below 70 mg/dL showed a statistically significant 22% reduction in major composite cardiovascular events (ischemic stroke, myocardial infarction, emergency revascularization of the coronary or carotid arteries, and cardiovascular death) (HR 0.78, 95% CI 0.61–0.98, P = 0.036) 61) ( Table 2 ) .
Table 2. Major Clinical Trials of Lipid-Lowering Therapy and Stroke.
| Trial | Study Population | Intervention / Comparator | Achieved LDL-C (mg/dL) [Intervention vs Control] |
Main Results for Stroke and Cerebrovascular Events |
Key Findings |
|---|---|---|---|---|---|
| SPARCL (2006) |
Recent stroke or TIA without known coronary heart disease |
Atorvastatin 80 mg vs placebo | 73 vs 129 mg/dL |
Total stroke reduced by 16% (HR 0.84, P = 0.03); ischemic stroke reduced (HR 0.78), whereas hemorrhagic stroke increased (HR 1.66). |
In secondary stroke prevention, statin therapy significantly reduced ischemic stroke recurrence; although hemorrhagic stroke increased, the overall benefit favored treatment. |
| J-STARS (2015) | Japanese patients with non- cardioembolic ischemic stroke |
Pravastatin 10 mg vs control (standard therapy) |
118 vs 127 mg/dL | No significant difference in overall recurrent stroke. Reduced recurrence of atherothrombotic infarction. | In Japanese patients with cerebral infarction, pravastatin reduced recurrence of atherothrombotic stroke, although the reduction in overall recurrent stroke was not significant. |
| TST (2020) |
Recent ischemic stroke or TIA with evidence of atherosclerosis |
Target LDL-C <70 mg/dL vs target LDL-C 90–110 mg/ dL |
65 vs 96 mg/dL | Reduced the primary composite cardiovascular endpoint (HR 0.78), but not recurrent stroke alone. |
In secondary stroke prevention, intensive lipid management targeting an LDL-C level <70 mg/dL reduced cardiovascular events. |
| ASSORT (2017) | Acute ischemic stroke with dyslipidemia | Statin within 24 h of admission vs delayed initiation (day 7) | Early initiation vs delayed initiation of statin therapy | No significant difference in the modified Rankin Scale score at 90 days. | Early statin initiation did not improve 90-day functional outcomes, with no significant difference in safety outcomes. |
| INSPIRES (2024) | Mild ischemic stroke or high- risk TIA from atherosclerosis within 72 h of onset | Early intensive statin therapy vs 3-day delayed-intensive statin therapy | Both groups received intensive statin therapy (protocol comparison) |
No reduction in 90-day recurrent stroke (8.1% vs 8.4%; HR 0.95); a favorable shift in functional outcome was observed (common OR 0.83). |
Immediate-intensive statin therapy did not reduce 90-day recurrent stroke but was associated with a favorable shift in mRS. |
|
HPS (2004) * Prior stroke subgroup analysis |
Patients with prior stroke (subgroup analysis; n = 3,280) * |
Simvastatin 40 mg vs placebo | 92 vs 131 mg/dL | No significant reduction in recurrent stroke among patients with previous stroke (10.3% vs 10.4%). | Stroke was reduced by approximately 25% in the overall high-risk population, but no reduction in recurrent stroke was observed in patients with previous stroke. |
|
FOURIER (2026) * Prior stroke subgroup analysis |
Patients with previous ischemic stroke (n = 5,291) * |
Statin + evolocumab vs statin + placebo |
<20, 20–<40, 40–<55, 55–<70, and ≥70 mg/dL |
Lower achieved LDL-C was associated with reduced recurrent ischemic stroke without increased hemorrhagic stroke. |
Very low achieved LDL-C levels, including <20 mg/ dL, were not associated with an increased risk of hemorrhagic stroke. |
5-6. Concerns Regarding Intracerebral Hemorrhage and Safety Assessment
The risk of hemorrhagic stroke associated with aggressive lipid-lowering therapy remains a subject of ongoing debatable. In the SPARCL trial, high-dose atorvastatin was associated with an increased risk of hemorrhagic stroke, raising concerns about its safety. However, a meta-analysis of all randomized controlled trials, not limited to patients with stroke, reported that there was no clear increase in the risk of hemorrhagic stroke with statins or that any increase was mild 62) . In contrast, a meta-analysis limited to patients with a history of stroke or TIA suggested that statin therapy may increase the risk of hemorrhagic stroke (RR 1.46, 95% CI 1.05–2.04). However, when the benefits of lipid-lowering therapy in reducing the recurrence of ischemic stroke and major cardiovascular events are considered, the overall clinical benefit outweighs the risk of bleeding 63) . This analysis also found no significant increase in hemorrhagic stroke associated with PCSK9 inhibitors or ezetimibe. Similarly, in an exploratory analysis of 5,291 patients with a history of ischemic stroke who participated in the FOURIER and FOURIER-OLE trials, no increase in hemorrhagic stroke was observed even when target LDL-C levels were below 40 mg/dL or even below 20 mg/dL, and no clear association was demonstrated between extremely low LDL-C levels and hemorrhagic stroke 64) . Based on the above, in routine secondary prevention of ischemic stroke, the benefit of lipid-lowering therapy in reducing ischemic events is considered to outweigh the risk of hemorrhagic stroke. In patients with a history of intracerebral hemorrhage, multiple lobar microbleeds, superficial cortical iron deposition, or findings suggestive of cerebral amyloid angiopathy, treatment decisions may need to be made based on the individual risks of both hemorrhage and ischemia.
5-7. Large-scale clinical trials involving Japanese participants (MEGA, JELIS, J-STARS, etc.)
Following large-scale clinical trials in Europe and the United States, randomized controlled trials conducted in Japan have also reported that lipid-lowering therapy and eicosapentaenoic acid (EPA) preparations are effective in reducing cardiovascular and cerebrovascular events (CVE). The MEGA study, which focused on primary prevention in Japanese patients with no history of coronary artery disease or stroke, enrolled 7,832 participants; while pravastatin reduced the risk of coronary artery disease by 33%, no significant difference was observed in the incidence of stroke 65) . Additionally, 18,645 patients were enrolled in the JELIS study; while the addition of EPA to statin therapy reduced major coronary events by 19%, the overall stroke incidence remained unchanged 66) . However, in a subgroup analysis of patients with a history of stroke, the addition of EPA reduced stroke recurrence by approximately 20%, demonstrating its utility in secondary prevention 67) .
The J-STARS trial, which enrolled patients with a history of non-cardioembolic ischemic stroke, included 1,578 participants. Although no significant difference was observed in the primary endpoint of overall stroke recurrence, a recurrence-reducing effect was suggested for atherothrombotic ischemic stroke 68) . Furthermore, in the EMPATHY trial, which enrolled 5,042 patients with diabetes and retinopathy, no significant difference was observed in the primary composite endpoint, but exploratory analyses revealed a significant reduction in the incidence of stroke and TIA 69) . In the REAL-CAD trial (13,054 patients enrolled), which enrolled patients with stable coronary artery disease, high-dose pitavastatin significantly reduced major cardiovascular events by 19% 70) . Therefore, while the preventive effect against stroke alone is limited in general primary prevention among Japanese patients, it has been demonstrated that in high-risk patients—such as those with a history of stroke, diabetes, or coronary artery disease—aggressive LDL-C-lowering therapy and the concomitant use of EPA preparations contribute not only to the suppression of cerebrovascular events but also to that of cardiovascular events.
5-8. Lipid-lowering therapy during the acute phase of ischemic stroke (ASSORT, INSPIRES, etc.)
Although the efficacy of statins in the secondary prevention of ischemic stroke is well established, there is insufficient evidence regarding when and at what intensity lipid-lowering therapy should be initiated during the acute phase of ischemic stroke. A study of 89 patients who had been taking statins prior to onset reported that discontinuing statins for 3 days during the acute phase resulted in a 4.7-fold increase in the odds ratio for death or loss of independence and an 8.7-fold increase in the frequency of neurological symptom worsening, demonstrating the importance of continuing statin therapy during the acute phase 71) . An observational study of 631 patients with acute ischemic stroke reported that patients who had been taking statins before onset had a higher proportion of favorable outcomes, regardless of stroke subtype 72) . In a subgroup analysis of the SPARCL trial focusing on carotid stenosis (1,007 patients), the stroke- and cardiovascular event-preventive effects of high-dose atorvastatin were observed regardless of the presence or absence of carotid stenosis 73) .
Against this backdrop, a randomized trial of early statin initiation in patients with acute ischemic stroke was initiated; however, it was terminated early due to insufficient patient enrollment, and no conclusions regarding efficacy could be drawn from it 74) . Studies on revascularization and lipid-lowering therapies have also been conducted. In the STARS study, the safety of simvastatin (40 mg) was evaluated in 104 patients who underwent thrombolytic therapy or thrombectomy within 12 h of symptom onset, and no safety concerns were identified with acute-phase administration 75) . A study involving 261 patients who underwent thrombectomy reported that early initiation of the PCSK9 inhibitor evolocumab was associated with favorable outcomes at discharge 76) .
Although these studies were small in scale, prospective evidence supporting the efficacy of acute-phase lipid-lowering therapy remains limited. The ASSORT trial, conducted in Japan, was a randomized trial comparing an early intervention group—in which statins were initiated within 24 h of hospitalization—with a deferred-intervention group—in which statins were initiated on the 7th hospital day—in patients with acute ischemic stroke and dyslipidemia. No significant difference was observed in the distribution of the modified Rankin Scale scores at 90 days (the primary endpoint), and the superiority of early initiation was not demonstrated 77) .
The INSPIRES trial randomized 6,100 patients with mild ischemic stroke or high-risk TIA due to presumed atherosclerosis within 72 h of symptom onset to immediate-intensive statin therapy or a 3-day delayed-intensive statin regimen. There was no significant difference in recurrent stroke within 90 days (8.1% vs. 8.4%; HR 0.95, 95% CI 0.80–1.13). However, the immediate treatment group had a lower rate of poor functional outcomes at 90 days (OR 0.83, 95% CI 0.71–0.98). Furthermore, according to the GUSTO criteria for safety assessment, the incidence of moderate-to-severe bleeding was 0.8% vs. 0.6%, indicating that the treatment could be safely administered. Additionally, a subgroup analysis showed a trend toward the effectiveness of early aggressive statin therapy in the group treated within 24 h of symptom onset 78) ( Table 2 ) .
6.New Treatments for Dyslipidemia and the Challenge of Residual Risk ( Fig.3 )
Fig.3.

Evolution of Novel Lipid-Lowering Therapies (2007–2026)
6-1. Interventions Targeting Triglycerides (TG) and HDL-C
Large-scale randomized controlled trials have been conducted to evaluate the effects of fibrate-class drugs on the reduction of cardiovascular events. In the FIELD trial, which enrolled 9,795 patients with type 2 diabetes, although fenofibrate 200 mg did not significantly reduce the primary endpoint consisting of coronary death or nonfatal myocardial infarction, it reduced nonfatal myocardial infarction by 24% and demonstrated protective effects against diabetic retinopathy, nephropathy, and lower limb amputations, without significant difference in the incidence of stroke 79) . Furthermore, in the ACCORD-Lipid trial involving 5,518 patients with type 2 diabetes, the addition of fenofibrate to simvastatin did not significantly reduce the primary endpoint, comprising nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death, nor did it result in a difference in the incidence of stroke. In a subgroup with hypertriglyceridemia and low HDL cholesterol—defined as triglycerides ≥ 204 mg/dL and HDL cholesterol ≤ 34 mg/dL—there were indications of a beneficial effect in reducing cardiovascular events 80) .
The effects of niacin therapy were also investigated. In the AIM-HIGH trial, which enrolled 3,414 patients with atherosclerotic cardiovascular disease receiving statin therapy, the addition of sustained-release niacin to simvastatin (combined with ezetimibe as needed) did not reduce the primary endpoint—comprising coronary death, nonfatal myocardial infarction, ischemic stroke, hospitalization due to acute coronary syndrome, and coronary revascularization; although ischemic stroke did not increase significantly, a trend toward higher rates was observed in the niacin group, and the trial was terminated early 81) . In the HPS2-THRIVE trial involving 25,673 patients with a history of cardiovascular disease, the addition of niacin/laropiprant to statin therapy did not significantly reduce the primary vascular events, including coronary death, myocardial infarction, stroke, and revascularization, and showed no difference in the incidence of stroke. Conversely, there was an increase in adverse events, including new-onset diabetes and worsening of diabetic control, and the benefits of niacin add-on therapy were not demonstrated 82) .
Several large-scale clinical trials have been conducted on n-3 polyunsaturated fatty acid preparations. In the REDUCE-IT trial, which enrolled 8,179 patients with controlled LDL cholesterol and hypertriglyceridemia (135–499 mg/dL), the addition of 4 g/day of icosapent ethyl resulted in a 25% reduction in the primary endpoint—comprising cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, and unstable angina—, and fatal and nonfatal strokes by 28% 83) . In the EVAPORATE trial involving 80 patients with coronary artery disease or at high risk for it, 4 g/day of icosapent ethyl significantly suppressed the progression of coronary artery plaques, including low-density plaques, as seen on coronary computed tomography (CT) 84) . In contrast, in the STRENGTH trial, which enrolled 13,078 patients with hypertriglyceridemia (180–500 mg/dL), the addition of 4 g/day of omega-3 carboxylic acid supplements did not significantly reduce the primary endpoint—comprising cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, and unstable angina, and no effect on reducing cardiovascular events was observed 85) .
6-2. The Integration of Inflammation Control and Dyslipidemia
The importance of controlling inflammation is also gaining attention in the treatment of dyslipidemia. The JUPITER trial, which enrolled 17,802 patients without a history of cardiovascular disease, reported that administration of 20 mg of rosuvastatin to patients with LDL cholesterol levels below 130 mg/dL and high-sensitivity CRP levels of 2.0 mg/L or higher significantly reduced major cardiovascular events and reduced the incidence of stroke by 48% 86) . The CANTOS trial, which enrolled 10,061 patients with a history of myocardial infarction and high-sensitivity CRP levels of 2 mg/L or higher, found that the IL-1β inhibitor canakinumab significantly reduced the primary endpoint—comprising nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death—but showed no significant difference in the incidence of stroke alone 87) .
6-3. PCSK9-Targeted Therapy and New Lipid-Lowering Drugs
Large-scale clinical trials of lipid-lowering therapy targeting PCSK9 have also been reported. In the ODYSSEY OUTCOMES trial, which enrolled 18,924 patients within one year of acute coronary syndrome, the addition of the PCSK9 inhibitor alirocumab resulted in a 15% reduction in the primary endpoint—comprising cardiovascular death, nonfatal myocardial infarction, fatal and nonfatal ischemic strokes, and hospitalizations due to unstable angina, and fatal and nonfatal ischemic strokes by 27% 88) . Furthermore, in the ORION-10 and ORION-11 trials (1,561 and 1,617 patients, respectively), which enrolled patients with ASCVD or those at equivalent risk of ASCVD, it was reported that inclisiran, an siRNA agent that inhibits PCSK9 synthesis, reduced LDL cholesterol by 52% and 50%, respectively, demonstrating a long-lasting LDL-lowering effect 89) . In the HUYGENS trial involving 164 patients following acute coronary syndrome, the addition of the PCSK9 inhibitor evolocumab to statin therapy was associated with an increase in fibrous cap thickness and a reduction in lipid core volume as assessed by optical coherence tomography, suggesting stabilization of coronary artery plaques 90) . Subsequently, in the VESALIUS-CV trial, which enrolled 12,257 patients at high risk for primary prevention, the PCSK9 inhibitor evolocumab reduced the primary endpoint—comprising coronary heart disease death, myocardial infarction, and ischemic stroke—by 25% and also reduced a composite endpoint that included coronary revascularization by 19%, though no significant reduction was observed for ischemic stroke alone 91) .
The development of new dyslipidemia treatments other than PCSK9 inhibitors is also progressing. In the PROMINENT trial, which enrolled 10,497 patients with diabetes, hypertriglyceridemia, and low HDL cholesterol, adding pemafibrate—a SPPARMα—to statin therapy did not result in a significant reduction in the primary endpoint consisting of cardiovascular death, nonfatal myocardial infarction, ischemic stroke, and coronary revascularization, though improvements in lipid and metabolic markers—such as reductions in TG and remnant lipoprotein-related parameters, increases in HDL-C, and improvements in liver function—were observed 92) . In the CLEAR Outcomes trial, which enrolled 13,970 patients with a history of ASCVD or at high risk, the ACL inhibitor bempedoic acid reduced LDL cholesterol by 26%, high-sensitivity CRP by approximately 20%, and the primary endpoint—comprising cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and coronary revascularization—was reduced by 13%. No significant difference was observed between stroke and stroke alone 93) . A meta-analysis of lipid-lowering therapies showed that, in addition to lowering LDL-C, bempedoic acid also has a relatively strong effect on reducing high-sensitivity CRP, suggesting that it may reduce cardiovascular risk through both lipid-lowering and anti-inflammatory effects 94) .
6-4. Lipoprotein(a) [Lp(a)] and Expectations for Next-Generation CETP Inhibitors
In recent years, Lp(a) has garnered attention as a therapeutic target for residual risk. Pelacarsen, an antisense oligonucleotide, is currently undergoing the Phase III HORIZON trial in patients with ASCVD 95) and Olpasiran, an siRNA agent, reduced Lp(a) by more than 90% in a Phase II trial, and the Phase III OCEAN(a)-Outcomes trial is currently underway (ClinicalTrials.gov Identifier: NCT05581303). Furthermore, Lepodisiran, a long-acting siRNA formulation, has been reported to significantly reduce Lp(a) levels over an extended period following a single dose, and Lp(a)-targeted therapies are expected to be applied in the future to reduce cardiovascular events 96) .
CETP mediates the exchange of cholesteryl esters and TG between HDL and apolipoprotein B-containing lipoproteins. CETP inhibitors were originally developed to increase HDL-C levels by blocking this lipid exchange and were subsequently found to reduce LDL-C and other apoB-containing lipoproteins. In the ILLUMINATE trial involving 15,067 patients at high cardiovascular risk, despite a 72% increase in HDL-C and a 25% decrease in LDL-C following the addition of torcetrapib, coronary events increased by 25% and all-cause mortality increased by 58%, leading to the early termination of the trial 97) . In the subsequent dal-OUTCOMES trial, which enrolled 15,871 patients with acute coronary syndrome, dalcetrapib increased HDL-C by 31–40% but failed to reduce major cardiovascular events, such as cardiovascular death, nonfatal myocardial infarction, and stroke 98) . In the ACCELERATE trial, which enrolled 12,092 patients with recent acute coronary syndrome, atherothrombotic stroke, or peripheral artery disease, evacetrapib reduced LDL-C by 31% and increased HDL-C by 133%; however, no reduction in major cardiovascular events was observed, and the trial was discontinued 99) . In the REVEAL trial, which enrolled 30,449 patients with atherosclerotic cardiovascular disease, the addition of anacetrapib increased HDL-C by 43 mg/dL and reduced non-HDL-C by 18%, resulting in a 9% reduction in major coronary events, defined as coronary death, myocardial infarction, and coronary revascularization 99 , 100) . These results suggest that the clinical benefit of CETP inhibitors may stem not from the increase in HDL-C itself, but rather from reductions in apoB-containing lipoproteins and LDL-C levels. Currently, a next-generation CETP inhibitor, obicetrapib, is under development. In the BROADWAY trial, it significantly reduced LDL cholesterol, apoB, and Lp(a) levels and is expected to serve as an oral lipid-lowering therapy with a potent LDL-lowering effect distinct from that of conventional CETP inhibitors. Results from large-scale clinical trials verifying the efficacy of this drug in reducing cardiovascular events are eagerly awaited.
7.Future Prospects in Clinical Practice for Ischemic Stroke ( Fig.4 )
Fig.4.

Concept of lipid-lowering therapy in acute ischemic stroke
Aggressive lipid-lowering therapy is an established strategy for the primary and secondary prevention of ASCVD, and its efficacy has been demonstrated in numerous clinical trials. In routine clinical practice, statins are frequently initiated soon after admission in patients with acute ischemic stroke. In the acute phase of ischemic stroke, the beneficial effects of statins may be attributable not only to LDL-C reduction but also to their pleiotropic effects, including improvement of endothelial function, anti-inflammatory and antioxidant actions, and enhancement of nitric oxide bioavailability 101) . These pleiotropic effects may contribute to early neurovascular protection, promote plaque stabilization, and reduce carotid plaque vulnerability, thereby potentially reducing artery-to-artery embolism. However, compared with reperfusion therapy or DAPT, prospective evidence supporting lipid-lowering therapy initiated during the early phase after stroke onset remains limited. One of the major reasons is that, unlike coronary artery disease, ischemic stroke is a heterogeneous disorder comprising atherothrombotic stroke, cardioembolic stroke, small vessel disease, embolic stroke of undetermined source, and other etiologies. Accordingly, the contribution of dyslipidemia and the benefits of lipid-lowering therapy are unlikely to be uniform across all stroke subtypes, highlighting the need for subtype- and stage-specific therapeutic strategies for stroke prevention.
Nevertheless, a wide range of lipid and inflammatory biomarkers, together with vascular imaging modalities, are available for evaluating patients with ischemic stroke. Integrating lipid markers—including ApoB, non-HDL cholesterol, TG, remnant cholesterol, small dense LDL, and Lp(a)—with inflammatory biomarkers such as hs-CRP, combined with carotid ultrasonography, carotid MRI, and intracranial vessel wall MRI, may improve prediction of stroke recurrence, enable more comprehensive risk assessment, and facilitate identification of patients most likely to benefit from intensive lipid-lowering therapy.
In addition, as mentioned in this review, therapeutic options for dyslipidemia have substantially expanded. The growing number of agents with distinct mechanisms of action provides an opportunity to move beyond statin monotherapy and develop mechanism-based combination strategies using ezetimibe, PCSK9 inhibitors, siRNA therapeutics, eicosapentaenoic acid preparations, ATP-citrate lyase inhibitors, and other emerging agents. Large-scale clinical trials have evaluated not only individual agents but also varying treatment intensities and combination strategies, substantially broadening the therapeutic landscape for dyslipidemia treatment.
Therefore, future clinical research should initially focus on patients with atherothrombotic stroke, in whom the pathophysiological link with dyslipidemia is the strongest and the greatest therapeutic benefit is anticipated. In particular, randomized trials evaluating whether intensive lipid-lowering strategies, including combination therapy initiated within the first 24 h after stroke onset, improve clinical outcomes are warranted. Subsequently, the treatment strategies for small-vessel disease should be explored, considering not only the lipid-lowering effects but also the anti-inflammatory and pleiotropic properties of these agents. In the chronic phase, further studies should evaluate the potential of these agents to prevent recurrent stroke and promote stabilization or regression of atherosclerotic vascular lesions. Early proof-of-concept studies in carefully selected patient populations may provide the foundation for larger randomized clinical trials and ultimately establish evidence-based lipid management tailored to individual stroke mechanisms.
Conflicts of Interest
The author declares that no conflicts of interest exist.
References
- 1).Okamura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S, Ohmura H, Shoji T, Yokote K, Yoshida H, Yoshida M, Deguchi J, Dobashi K, Fujiyoshi A, Hamaguchi H, Hara M, Harada-Shiba M, Hirata T, Iida M, Ikeda Y, Ishibashi S, Kanda H, Kihara S, Kitagawa K, Kodama S, Koseki M, Maezawa Y, Masuda D, Miida T, Miyamoto Y, Nishimura R, Node K, Noguchi M, Ohishi M, Saito I, Sawada S, Sone H, Takemoto M, Wakatsuki A, Yanai H. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022. J Atheroscler Thromb, 2024; 31: 641-853 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2).Imamura T, Doi Y, Arima H, Yonemoto K, Hata J, Kubo M, Tanizaki Y, Ibayashi S, Iida M, Kiyohara Y. LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hisayama study. Stroke, 2009; 40: 382-388 [DOI] [PubMed] [Google Scholar]
- 3).Tanizaki Y, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Shinohara N, Arima H, Tanaka K, Ibayashi S, Fujishima M. Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayama study. Stroke, 2000; 31: 2616-2622 [DOI] [PubMed] [Google Scholar]
- 4).Soyama Y, Miura K, Morikawa Y, Nishijo M, Nakanishi Y, Naruse Y, Kagamimori S, Nakagawa H, Study O. High-density lipoprotein cholesterol and risk of stroke in Japanese men and women: the Oyabe Study. Stroke, 2003; 34: 863-868 [DOI] [PubMed] [Google Scholar]
- 5).Noda H, Iso H, Saito I, Konishi M, Inoue M, Tsugane S, Group JS. The impact of the metabolic syndrome and its components on the incidence of ischemic heart disease and stroke: the Japan public health center-based study. Hypertens Res, 2009; 32: 289-298 [Google Scholar]
- 6).Blumenthal RS, Morris PB, Gaudino M, Johnson HM, Anderson TS, Bittner VA, Blankstein R, Brewer LC, Cho L, de Ferranti SD, Gianos E, Gluckman TJ, Gradney KF, Isiadinso I, Lloyd-Jones DM, Marrs JC, Martin SS, McLain KH, Mehta LS, Mora S, Mulugeta WM, Natarajan P, Navar AM, Orringer CE, Polonsky TS, Reynolds HR, Saseen JJ, Shapiro MD, Soffer DE, Tynes SA, Villavaso CD, Virani SS, Wilkins JT. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol, 2026; 87: 2624-2757 [DOI] [PubMed] [Google Scholar]
- 7).National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 2002; 106: 3143-3421 [PubMed] [Google Scholar]
- 8).Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, Benn M, Binder CJ, Catapano AL, De Backer GG, Delgado V, Fabin N, Ference BA, Graham IM, Landmesser U, Laufs U, Mihaylova B, Nordestgaard BG, Richter DJ, Sabatine MS, Group EESD. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J, 2025; 46: 4359-4378 [Google Scholar]
- 9).Nishi K, Itabe H, Uno M, Kitazato KT, Horiguchi H, Shinno K, Nagahiro S. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol, 2002; 22: 1649-1654 [DOI] [PubMed] [Google Scholar]
- 10).Mathiesen EB, Bønaa KH, Joakimsen O. Low levels of high-density lipoprotein cholesterol are associated with echolucent carotid artery plaques: the tromsø study. Stroke, 2001; 32: 1960-1965 [DOI] [PubMed] [Google Scholar]
- 11).Virani SS, Catellier DJ, Pompeii LA, Nambi V, Hoogeveen RC, Wasserman BA, Coresh J, Mosley TH, Otvos JD, Sharrett AR, Boerwinkle E, Ballantyne CM. Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) carotid MRI study. Atherosclerosis, 2011; 219: 596-602 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12).Zhao XQ, Dong L, Hatsukami T, Phan BA, Chu B, Moore A, Lane T, Neradilek MB, Polissar N, Monick D, Lee C, Underhill H, Yuan C. MR imaging of carotid plaque composition during lipid-lowering therapy a prospective assessment of effect and time course. JACC Cardiovasc Imaging, 2011; 4: 977-986 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13).Woo NE, Na HK, Heo JH, Nam HS, Choi JK, Ahn SS, Choi HS, Lee SK, Lee HS, Cha J, Kim YD. Factors for Enhancement of Intracranial Atherosclerosis in High Resolution Vessel Wall MRI in Ischemic Stroke Patients. Front Neurol, 2020; 11: 580 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14).Suri MF, Qiao Y, Ma X, Guallar E, Zhou J, Zhang Y, Liu L, Chu H, Qureshi AI, Alonso A, Folsom AR, Wasserman BA. Prevalence of Intracranial Atherosclerotic Stenosis Using High-Resolution Magnetic Resonance Angiography in the General Population: The Atherosclerosis Risk in Communities Study. Stroke, 2016; 47: 1187-1193 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15).Zhang P, Zhang Z, Li D, Han R, Li H, Ma J, Xu P, Qi Z, Liu L, Zhang A. Association of remnant cholesterol with intracranial atherosclerosis in community-based population: The ARIC study. J Stroke Cerebrovasc Dis, 2023; 32: 107293 [DOI] [PubMed] [Google Scholar]
- 16).Chaturvedi S, Turan TN, Lynn MJ, Kasner SE, Romano J, Cotsonis G, Frankel M, Chimowitz MI, Group WS. Risk factor status and vascular events in patients with symptomatic intracranial stenosis. Neurology, 2007; 69: 2063-2068 [DOI] [PubMed] [Google Scholar]
- 17).Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF, Hoh BL, Hourihane JM, Levy EI, Alexandrov AV, Harrigan MR, Chiu D, Klucznik RP, Clark JM, McDougall CG, Johnson MD, Pride GL, Torbey MT, Zaidat OO, Rumboldt Z, Cloft HJ, Investigators ST. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med, 2011; 365: 993-1003 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18).Tomochika Y, Tanaka N, Ono S, Murata K, Muro A, Yamamura T, Tone T, Iwatate M, Ueda K, Morikuni K, Matsuzaki M. Assessment by transesophageal echography of atherosclerosis of the descending thoracic aorta in patients with hypercholesterolemia. Am J Cardiol, 1999; 83: 703-709 [DOI] [PubMed] [Google Scholar]
- 19).Okuzumi A, Ueno Y, Shimada Y, Tanaka Y, Miyamoto N, Yamashiro K, Tanaka R, Hattori N, Urabe T. Impact of low-density lipoprotein to high-density lipoprotein ratio on aortic arch atherosclerosis in unexplained stroke. J Neurol Sci, 2013; 326: 83-88 [DOI] [PubMed] [Google Scholar]
- 20).Yonemura A, Momiyama Y, Fayad ZA, Ayaori M, Ohmori R, Higashi K, Kihara T, Sawada S, Iwamoto N, Ogura M, Taniguchi H, Kusuhara M, Nagata M, Nakamura H, Tamai S, Ohsuzu F. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J Am Coll Cardiol, 2005; 45: 733-742 [DOI] [PubMed] [Google Scholar]
- 21).Kohsaka S, Jin Z, Rundek T, Homma S, Sacco RL, Di Tullio MR. Relationship between serum lipid values and atherosclerotic burden in the proximal thoracic aorta. Int J Stroke, 2010; 5: 257-263 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22).Li S, Dong L, Huang Q, Xu J, Xu Z, Mao X, Tang J, Li X, Lin J, Hong D. Dyslipidemia is associated with progressive infarction in anterior circulation single subcortical infarction patients. J Stroke Cerebrovasc Dis, 2023; 32: 107387 [DOI] [PubMed] [Google Scholar]
- 23).Yamamoto Y, Ohara T, Hamanaka M, Hosomi A, Tamura A, Akiguchi I. Characteristics of intracranial branch atheromatous disease and its association with progressive motor deficits. J Neurol Sci, 2011; 304: 78-82 [DOI] [PubMed] [Google Scholar]
- 24).Lin J, Dong L, Huang Q, Xiao H, Li S, Tang J, Mao X, Huang P, Li X, Hong D. TG/HDL-c ratio as a predictor of progressive infarction in patients with anterior circulation single subcortical infarction. Brain Behav, 2024; 14: e3453 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25).Ryu WS, Schellingerhout D, Jeong SW, Nahrendorf M, Kim DE. Association between Serum Lipid Profiles and Early Neurological Deterioration in Acute Ischemic Stroke. J Stroke Cerebrovasc Dis, 2016; 25: 2024-2030 [DOI] [PubMed] [Google Scholar]
- 26).Nam KW, Kang MK, Jeong HY, Kim TJ, Lee EJ, Bae J, Jeon K, Jung KH, Ko SB, Yoon BW. Triglyceride-glucose index is associated with early neurological deterioration in single subcortical infarction: Early prognosis in single subcortical infarctions. Int J Stroke, 2021; 16: 944-952 [DOI] [PubMed] [Google Scholar]
- 27).Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J, Collaboration ERF. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet, 2010; 375: 132-140 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28).Matsuo R, Ago T, Hata J, Wakisaka Y, Kuroda J, Kuwashiro T, Kitazono T, Kamouchi M, Investigators FSR. Plasma C-Reactive Protein and Clinical Outcomes after Acute Ischemic Stroke: A Prospective Observational Study. PLoS One, 2016; 11: e0156790 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29).Ridker PM, Moorthy MV, Cook NR, Rifai N, Lee IM, Buring JE. Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women. N Engl J Med, 2024; 391: 2087-2097 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30).Nordestgaard AT, Moorthy MV, Cook NR, Rifai N, Lee IM, Buring JE, Ridker PM. High-sensitivity C-reactive protein, LDL cholesterol, lipoprotein(a) and 30-year risk of stroke in healthy women: a prospective, longitudinal cohort study. The Lancet Neurology, 2025; 24: 920-930 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31).Tsimikas S, Witztum JL. Oxidized phospholipids in cardiovascular disease. Nature reviews Cardiology, 2024; 21: 170-191 [DOI] [PubMed] [Google Scholar]
- 32).Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J, 2017; 38: 2478-2486 [DOI] [PubMed] [Google Scholar]
- 33).Rosenson RS, Brewer HB, Jr., Ansell BJ, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nature reviews Cardiology, 2016; 13: 48-60 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34).Packard CJ, Boren J, Taskinen MR. Causes and Consequences of Hypertriglyceridemia. Frontiers in endocrinology, 2020; 11: 252 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35).Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. Journal of lipid research, 2002; 43: 1363-1379 [DOI] [PubMed] [Google Scholar]
- 36).KANNEL WB, DAWBER TR, KAGAN A, REVOTSKIE N, STOKES J. Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study. Ann Intern Med, 1961; 55: 33-50 [DOI] [PubMed] [Google Scholar]
- 37).Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med, 1971; 74: 1-12 [DOI] [PubMed] [Google Scholar]
- 38).Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett, 1976; 72: 323-326 [DOI] [PubMed] [Google Scholar]
- 39).Connelly D. Statins: the highs and the lows. Pharm J, 2018; 301: 156-157 [Google Scholar]
- 40).Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med, 1987; 317: 1237-1245 [DOI] [PubMed] [Google Scholar]
- 41).Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995; 333: 1301-1307 [DOI] [PubMed] [Google Scholar]
- 42).Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J, investigators A. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003; 361: 1149-1158 [DOI] [PubMed] [Google Scholar]
- 43).Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, investigators C. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004; 364: 685-696 [DOI] [PubMed] [Google Scholar]
- 44).Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J, Xavier D, Avezum A, Leiter LA, Piegas LS, Parkhomenko A, Keltai M, Keltai K, Sliwa K, Chazova I, Peters RJ, Held C, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Accini JL, McKelvie R, Pogue J, Jung H, Liu L, Diaz R, Dans A, Dagenais G, Investigators H-. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med, 2016; 374: 2032-2043 [DOI] [PubMed] [Google Scholar]
- 45).Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994; 344: 1383-1389 [PubMed] [Google Scholar]
- 46).Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med, 1996; 335: 1001-1009 [DOI] [PubMed] [Google Scholar]
- 47).Group L-TIwPiIDS. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med, 1998; 339: 1349-1357 [DOI] [PubMed] [Google Scholar]
- 48).Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, Risk PsgPSoPitEa. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, 2002; 360: 1623-1630 [DOI] [PubMed] [Google Scholar]
- 49).Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R, Investigators S. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet, 2011; 377: 2181-2192 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50).Group HPSC. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002; 360: 7-22 [DOI] [PubMed] [Google Scholar]
- 51).LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, Investigators TtNT. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005; 352: 1425-1435 [DOI] [PubMed] [Google Scholar]
- 52).Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, Investigators I-I. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med, 2015; 372: 2387-2397 [DOI] [PubMed] [Google Scholar]
- 53).Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, Investigators FSCa. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med, 2017; 376: 1713-1722 [DOI] [PubMed] [Google Scholar]
- 54).O’Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, Im K, Murphy SA, Flores-Arredondo JH, López JAG, Elliott-Davey M, Wang B, Monsalvo ML, Abbasi S, Sabatine MS. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. Circulation, 2022; 146: 1109-1119 [DOI] [PubMed] [Google Scholar]
- 55).Lee YJ, Lee SJ, Kim JW, Lee SH, Kim GS, Park JH, Cho JM, Kang WC, Yoon HJ, Kim WH, Lee JB, Jang JY, Shin S, Park IH, Kwon SU, Kim S, Hong SJ, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y, Kim BK, Investigators E-P. Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease. N Engl J Med, 2026; 394: 1365-1375 [DOI] [PubMed] [Google Scholar]
- 56).Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R, Collaboration CTT. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376: 1670-1681 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57).Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, Parish S, Peto R, Collins R, Group SotEoARiC, Collaborative H. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet, 2010; 376: 1658-1669 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58).Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R, Group SC. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med, 2008; 359: 789-799 [DOI] [PubMed] [Google Scholar]
- 59).Collins R, Armitage J, Parish S, Sleight P, Peto R, Group HPSC. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet, 2004; 363: 757-767 [DOI] [PubMed] [Google Scholar]
- 60).Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA, Investigators SPbARiCL. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med, 2006; 355: 549-559 [DOI] [PubMed] [Google Scholar]
- 61).Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Béjot Y, Cabrejo L, Cha JK, Ducrocq G, Giroud M, Guidoux C, Hobeanu C, Kim YJ, Lapergue B, Lavallée PC, Lee BC, Lee KB, Leys D, Mahagne MH, Meseguer E, Nighoghossian N, Pico F, Samson Y, Sibon I, Steg PG, Sung SM, Touboul PJ, Touzé E, Varenne O, Vicaut É, Yelles N, Bruckert E, Investigators TStT. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. N Engl J Med, 2020; 382: 9 [Google Scholar]
- 62).McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke, 2012; 43: 2149-2156 [DOI] [PubMed] [Google Scholar]
- 63).Bétrisey S, Haller ML, Efthimiou O, Speierer A, Del Giovane C, Moutzouri E, Blum MR, Aujesky D, Rodondi N, Gencer B. Lipid-Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc, 2024; 13: e030714 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64).Monguillon V, Kelly PJ, O’Donoghue ML, Park JG, Bohula EA, Saver JL, Atar D, Keech AC, Sever PS, Wang H, Paiva da Silva Lima G, Sabatine MS, Giugliano RP. Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke. Circulation, 2026; 153: 86-93 [DOI] [PubMed] [Google Scholar]
- 65).Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y, Group MS. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet, 2006; 368: 1155-1163 [DOI] [PubMed] [Google Scholar]
- 66).Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Investigators JElis. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet, 2007; 369: 1090-1098 [DOI] [PubMed] [Google Scholar]
- 67).Tanaka K, Ishikawa Y, Yokoyama M, Origasa H, Matsuzaki M, Saito Y, Matsuzawa Y, Sasaki J, Oikawa S, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, JELIS Investigators Jp. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke, 2008; 39: 2052-2058 [DOI] [PubMed] [Google Scholar]
- 68).Hosomi N, Nagai Y, Kohriyama T, Ohtsuki T, Aoki S, Nezu T, Maruyama H, Sunami N, Yokota C, Kitagawa K, Terayama Y, Takagi M, Ibayashi S, Nakamura M, Origasa H, Fukushima M, Mori E, Minematsu K, Uchiyama S, Shinohara Y, Yamaguchi T, Matsumoto M, Collaborators J-S. The Japan Statin Treatment Against Recurrent Stroke (J-STARS): A Multicenter, Randomized, Open-label, Parallel-group Study. EBioMedicine, 2015; 2: 1071-1078 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69).Itoh H, Komuro I, Takeuchi M, Akasaka T, Daida H, Egashira Y, Fujita H, Higaki J, Hirata KI, Ishibashi S, Isshiki T, Ito S, Kashiwagi A, Kato S, Kitagawa K, Kitakaze M, Kitazono T, Kurabayashi M, Miyauchi K, Murakami T, Murohara T, Node K, Ogawa S, Saito Y, Seino Y, Shigeeda T, Shindo S, Sugawara M, Sugiyama S, Terauchi Y, Tsutsui H, Ueshima K, Utsunomiya K, Yamagishi M, Yamazaki T, Yo S, Yokote K, Yoshida K, Yoshimura M, Yoshimura N, Nakao K, Nagai R, Investigators E. Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. Diabetes Care, 2018; 41: 1275-1284 [DOI] [PubMed] [Google Scholar]
- 70).Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, Ogawa T, Ozaki Y, Sakuma I, Nakagawa Y, Hibi K, Hiro T, Fukumoto Y, Hokimoto S, Miyauchi K, Yamazaki T, Ito H, Otsuji Y, Kimura K, Takahashi J, Hirayama A, Yokoi H, Kitagawa K, Urabe T, Okada Y, Terayama Y, Toyoda K, Nagao T, Matsumoto M, Ohashi Y, Kaneko T, Fujita R, Ohtsu H, Ogawa H, Daida H, Shimokawa H, Saito Y, Kimura T, Inoue T, Matsuzaki M, Nagai R. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial. Circulation, 2018; 137: 1997-2009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71).Blanco M, Nombela F, Castellanos M, Rodriguez-Yáñez M, García-Gil M, Leira R, Lizasoain I, Serena J, Vivancos J, Moro MA, Dávalos A, Castillo J. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology, 2007; 69: 904-910 [DOI] [PubMed] [Google Scholar]
- 72).Martínez-Sánchez P, Rivera-Ordóñez C, Fuentes B, Ortega-Casarrubios MA, Idrovo L, Díez-Tejedor E. The beneficial effect of statins treatment by stroke subtype. Eur J Neurol, 2009; 16: 127-133 [DOI] [PubMed] [Google Scholar]
- 73).Sillesen H, Amarenco P, Hennerici MG, Callahan A, Goldstein LB, Zivin J, Messig M, Welch KM, Investigators SPbARiCL. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke, 2008; 39: 3297-3302 [DOI] [PubMed] [Google Scholar]
- 74).Beer C, Blacker D, Bynevelt M, Hankey GJ, Puddey IB. A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan. Int J Stroke, 2012; 7: 104-111 [DOI] [PubMed] [Google Scholar]
- 75).Montaner J, Bustamante A, García-Matas S, Martínez-Zabaleta M, Jiménez C, de la Torre J, Rubio FR, Segura T, Masjuán J, Cánovas D, Freijo M, Delgado-Mederos R, Tejada J, Lago A, Bravo Y, Corbeto N, Giralt D, Vives-Pastor B, de Arce A, Moniche F, Delgado P, Ribó M, Investigators S. Combination of Thrombolysis and Statins in Acute Stroke Is Safe: Results of the STARS Randomized Trial (Stroke Treatment With Acute Reperfusion and Simvastatin). Stroke, 2016; 47: 2870-2873 [DOI] [PubMed] [Google Scholar]
- 76).Kim J, Hong U, Yoon CW, Bae JW, Rha JH, Park HK. PCSK9 inhibitor in acute ischemic stroke patient receiving mechanical thrombectomy: early outcomes and safety. Front Neurol, 2024; 15: 1375609 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77).Yoshimura S, Uchida K, Daimon T, Takashima R, Kimura K, Morimoto T, Investigator AT. Randomized Controlled Trial of Early Versus Delayed Statin Therapy in Patients With Acute Ischemic Stroke: ASSORT Trial (Administration of Statin on Acute Ischemic Stroke Patient). Stroke, 2017; 48: 3057-3063 [DOI] [PubMed] [Google Scholar]
- 78).Gao Y, Jiang L, Pan Y, Chen W, Jing J, Wang C, Johnston SC, Amarenco P, Bath PM, Yang Y, Wang T, Han S, Meng X, Lin J, Zhao X, Liu L, Zhao J, Li Y, Zang Y, Zhang S, Yang H, Yang J, Wang Y, Li D, Liu D, Kang G, Investigators I. Immediate- or Delayed-Intensive Statin in Acute Cerebral Ischemia: The INSPIRES Randomized Clinical Trial. JAMA Neurol, 2024; 81: 741-751 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79).Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d’Emden M, Whiting M, Ehnholm C, Laakso M, investigators Fs. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet, 2005; 366: 1849-1861 [DOI] [PubMed] [Google Scholar]
- 80).Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC, Cushman WC, Simons-Morton DG, Byington RP, Group AS. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med, 2010; 362: 1563-1574 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81).Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W, Investigators A-H. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med, 2011; 365: 2255-2267 [DOI] [PubMed] [Google Scholar]
- 82).Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J, Group H-TC. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med, 2014; 371: 203-212 [DOI] [PubMed] [Google Scholar]
- 83).Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM, Investigators R-I. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med, 2019; 380: 11-22 [DOI] [PubMed] [Google Scholar]
- 84).Budoff MJ, Bhatt DL, Kinninger A, Lakshmanan S, Muhlestein JB, Le VT, May HT, Shaikh K, Shekar C, Roy SK, Tayek J, Nelson JR. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J, 2020; 41: 3925-3932 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85).Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Ridker PM, Ray KK, Katona BG, Himmelmann A, Loss LE, Rensfeldt M, Lundström T, Agrawal R, Menon V, Wolski K, Nissen SE. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA, 2020; 324: 2268-2280 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86).Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, Group JS. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008; 359: 2195-2207 [DOI] [PubMed] [Google Scholar]
- 87).Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, Group CT. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med, 2017; 377: 1119-1131 [DOI] [PubMed] [Google Scholar]
- 88).Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM, Investigators OOCa. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med, 2018; 379: 2097-2107 [DOI] [PubMed] [Google Scholar]
- 89).Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP, Investigators O-, ORION-11. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med, 2020; 382: 1507-1519 [DOI] [PubMed] [Google Scholar]
- 90).Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, Hucko T, Aradi D, Herrman JR, Hermanides RS, Wang B, Wang H, Butters J, Di Giovanni G, Jones S, Pompili G, Psaltis PJ. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. JACC Cardiovasc Imaging, 2022; 15: 1308-1321 [DOI] [PubMed] [Google Scholar]
- 91).Bohula EA, Marston NA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, Park JG, Kuder JF, Murphy SA, Walsh E, Wang H, Blaha V, Budaj A, Cornel JH, Goudev A, Kiss RG, Lorenzatti AJ, Parkhomenko A, Cyrille M, Paiva da Silva Lima G, Ohman EM, Giugliano RP, Sabatine MS, Investigators V-C. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. N Engl J Med, 2026; 394: 117-127 [Google Scholar]
- 92).Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM, Investigators P. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med, 2022; 387: 1923-1934 [DOI] [PubMed] [Google Scholar]
- 93).Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, Thompson PD, Libby P, Cho L, Plutzky J, Bays HE, Moriarty PM, Menon V, Grobbee DE, Louie MJ, Chen CF, Li N, Bloedon L, Robinson P, Horner M, Sasiela WJ, McCluskey J, Davey D, Fajardo-Campos P, Petrovic P, Fedacko J, Zmuda W, Lukyanov Y, Nicholls SJ, Investigators CO. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med, 2023; 388: 1353-1364 [DOI] [PubMed] [Google Scholar]
- 94).Xie S, Galimberti F, Olmastroni E, Luscher TF, Carugo S, Catapano AL, Casula M, Group M-L. Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials. Cardiovasc Res, 2024; 120: 333-344 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 95).Cho L, Nicholls SJ, Nordestgaard BG, Landmesser U, Tsimikas S, Blaha MJ, Leitersdorf E, Lincoff AM, Lesogor A, Manning B, Kozlovski P, Cao H, Wang J, Nissen SE. Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a). Am Heart J, 2025; 287: 1-9 [DOI] [PubMed] [Google Scholar]
- 96).Nissen SE, Ni W, Shen X, Wang Q, Navar AM, Nicholls SJ, Wolski K, Michael L, Haupt A, Krege JH, Investigators AT. Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a). N Engl J Med, 2025; 392: 1673-1683 [DOI] [PubMed] [Google Scholar]
- 97).Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B, Investigators I. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med, 2007; 357: 2109-2122 [DOI] [PubMed] [Google Scholar]
- 98).Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS, Investigators d-O. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med, 2012; 367: 2089-2099 [DOI] [PubMed] [Google Scholar]
- 99).Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE, Investigators A. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med, 2017; 376: 1933-1942 [DOI] [PubMed] [Google Scholar]
- 100).Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ, Group HTRC. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med, 2017; 377: 1217-1227 [DOI] [PubMed] [Google Scholar]
- 101).Endres M. Statins and stroke. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism, 2005; 25: 1093-1110 [DOI] [PubMed] [Google Scholar]
